MAPK10 and rheumatoid arthritis: Thus, PharmMapper analysis supported the role of JNK1 and JNK3 as targets for TRYP-Ox, which is relevant to therapeutic intervention in RA, whereas no obvious targets related to RA intervention were found for TRYP.